Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Submitted by
admin
on June 4, 2016 - 6:27pm
Source:
Yahoo
News Tags:
Five Prime
ASCO 2016
mesothelioma
FP-1039
Headline:
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Do Not Allow Advertisers to Use My Personal information
